Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer

Journal of Clinical Oncology

Volumn 30, Issue 13, 2012, Pages 1468-1475

  Ito, Kouta ^a   Blinder, Victoria S ^b   Elkin, Elena B ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ADULT; ARTICLE; BONE DENSITY; BREAST CANCER; CLINICAL PRACTICE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; FRAGILITY FRACTURE; HIDDEN MARKOV MODEL; HUMAN; OSTEOPENIA; OSTEOPOROSIS; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCREENING; AGE; BREAST TUMOR; CANCER STAGING; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; DISEASE FREE SURVIVAL; DRUG COST; DRUG EFFECT; EARLY DIAGNOSIS; ECONOMICS; ENZYMOLOGY; FRACTURE; METABOLIC BONE DISEASE; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHOTON ABSORPTIOMETRY; PREDICTIVE VALUE; PROBABILITY; RADIOGRAPHY; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

ABSORPTIOMETRY, PHOTON; ADMINISTRATION, ORAL; AGE FACTORS; AROMATASE INHIBITORS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; BREAST NEOPLASMS; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DIPHOSPHONATES; DISEASE-FREE SURVIVAL; DRUG COSTS; EARLY DETECTION OF CANCER; FEMALE; FRACTURES, BONE; HUMANS; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; NEOPLASM STAGING; OSTEOPOROSIS; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; QUALITY-ADJUSTED LIFE YEARS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84862976452     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.7001     Document Type: Article

References (72)

1. Burstein HJ, Prestrud AA, Seidenfeld J, et al: American Society of Clinical Oncology Clinical Practice Guideline: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:3784-3796, 2010
2. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology: Breast cancer. V2. 2011. http://www.nccn.org/professionals/physician- gls/f-guidelines.asp
3. Chien AJ, Goss PE: Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol 24:5305-5312, 2006 (Pubitemid 46631378)
4. Saad F, Adachi JD, Brown JP, et al: Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol 26:5465-5476, 2008
5. Brufsky AM, Bosserman LD, Caradonna RR, et al: Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 9:77-85, 2009
6. Eidtmann H, de Boer R, Bundred N, et al: Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-Month results of ZO-FAST study. Ann Oncol 21:2188-2194, 2008
7. Brufsky A, Bundred N, Coleman R, et al: Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 13:503-514, 2008 (Pubitemid 351872868)
8. Confavreux CB, Fontana A, Guastalla JP, et al: Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole: Prevention with bisphosphonates. Bone 41:346-352, 2007 (Pubitemid 47199159)
9. Singh S, Cuzick J, Edwards R, et al: Effect of anastrozole on bone mineral density after one year of treatment: Results from bone sub-study of the International Breast Cancer Intervention Study (IBCS-II). Breast Cancer Res Treat 106:S9, 2007 (suppl 1; abstr 28)
10. Greenspan SL, Brufsky A, Lembersky BC, et al: Risedronate prevents bone loss in breast cancer survivors: A 2-year, randomized, double-blinded, placebo-controlled clinical trial. J Clin Oncol 26:2644-2652, 2008
11. Van Poznak C, Hannon RA, Mackey JR, et al: Prevention of aromatase inhibitor-induced bone loss using risedronate: The SABRE trial. J Clin Oncol 28:967-975, 2010
12. Markopoulos C, Tzoracoleftherakis E, Polychronis A, et al: Management of anastrozoleinduced bone loss in breast cancer patients with oral risedronate: Results from the ARBI prospective clinical trial. Breast Cancer Res 12:R24, 2010
13. Lester J, Dodwell D, Purohit OP, et al: Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 14:6336-6342, 2008
14. Saarto T, Vehmanen L, Elomaa I, et al: The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer. Br J Cancer 84:1047-1051, 2001 (Pubitemid 32448500)
15. Ellis GK, Bone HG, Chlebowski R, et al: Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26:4875-4882, 2008
16. Hillner BE, Ingle JN, Chlebowski RT, et al: American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042-4057, 2003 (Pubitemid 46606220)
17. Gralow JR, Biermann JS, Farooki A, et al: NCCN Taskforce Report: Bone health in cancer care. J Natl Compr Canc Netw 7:S1-S35, 2009 (suppl 3)
18. Body JJ, Bergmann P, Boonen S, et al: Management of cancer treatment-induced bone loss in early breast and prostate cancer: A consensus paper of the Belgian Bone Club. Osteoporos Int 18:1439-1450, 2007 (Pubitemid 47512686)
19. Reid DM, Doughty J, Eastell R, et al: Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group. Cancer Treat Rev 34:S3-S18, 2008 (suppl 1)
20. Aapro M, Abrahamsson PA, Body JJ, et al: Guidance on the use of bisphosphonates in solid tumours: Recommendations of an international expert panel. Ann Oncol 19:420-432, 2008
21. Hadji P, Aapro MS, Body JJ, et al: Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: Practical guidance for prevention and treatment. Ann Oncol 22:2546-2555, 2011
22. Ito K, Elkin EB, Girotra M, et al: Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. Ann Intern Med 152:621-629, 2010
23. Gold MR, Siegel JE, Russell LB, et al: Cost-Effectiveness in Health and Medicine. New York, NY, Oxford University Press, 1996
24. Giordano SH, Duan Z, Kuo YF, et al: Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 24:2750-2756, 2006 (Pubitemid 46630572)
25. Greep NC, Giuliano AE, Hansen NM, et al: The effects of adjuvant chemotherapy on bone density in postmenopausal women with early breast cancer. Am J Med 114:653-659, 2003 (Pubitemid 36703234)
26. National Cancer Institute: Surveillance, Epidemiology, and End Results: SEER stat fact sheet: Breast. http://seer.cancer.gov/statfacts/html/breast.html
27. Eastell R, Adams JE, Coleman RE, et al: Effect of anastrozole on bone mineral density: 5-Year results from the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230. J Clin Oncol 26:1051-1057, 2008
28. Looker AC, Wahner HW, Dunn WL, et al: Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8:468-489, 1998 (Pubitemid 28486716)
29. Ensrud KE, Palermo L, Black DM, et al: Hip and calcaneal bone loss increase with advancing age: Longitudinal results from the study of osteoporotic fractures. J Bone Miner Res 10:1778-1787, 1995
30. Burge R, Dawson-Hughes B, Solomon DH, et al: Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 22:465-475, 2007 (Pubitemid 46797130)
31. Johnell O, Kanis JA, Oden A, et al: Predictive value of BMD for hip and other fractures. J Bone Miner Res 20:1185-1194, 2005 (Pubitemid 40863806)
32. Kanis JA, Johnell O, De Laet C, et al: A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375-382, 2004 (Pubitemid 38953182)
33. National Center for Health Statistics: United States life tables, 2006. http://www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58-21.pdf
34. Haentjens P, Magaziner J, Colón-Emeric CS, et al: Meta-analysis: Excess mortality after hip fractures among older men and women. Ann Intern Med 152:380-390, 2010
35. Black DM, Schwartz AV, Ensrud KE, et al: Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-Term Extension (FLEX): A randomized controlled trial. JAMA 296:2927-2938, 2006 (Pubitemid 46021497)
36. Delea TE, Karnon J, Sofrygin O, et al: Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer. Clin Breast Cancer 7:608-618, 2007 (Pubitemid 47025818)
37. Delea TE, El-Ouagari K, Karnon J, et al: Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective. Breast Cancer Res Treat 108:375-387, 2008 (Pubitemid 351431071)
38. Sorensen S, Brown R, Benedict A, et al: Patient-rated utilities in postmenopausal early breast cancer: A cross country comparison. Value Health 7:641-642, 2004
39. Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, et al: Cost-effectiveness osteoporosis treatment thresholds: The United States perspective. Osteoporos Int 19:437-447, 2008
40. Kanis JA, Johnell A, Oden A, et al: The risk and burden of vertebral fractures in Sweden. Osteoporos Int 15:20-26, 2004 (Pubitemid 38252435)
41. Lamerato L, Havstad S, Gandhi SK, et al: The economic burden of breast cancer recurrence: Findings from a retrospective analysis of health system data. Presented at the 27th Annual San Antonio Breast Cancer Symposium, San Antonia, TX, December 8-11, 2004
42. Gabriel SE, Tosteson AN, Leibson CL, et al: Direct medical costs attributable to osteoporotic fractures. Osteoporos Int 13:323-330, 2002 (Pubitemid 34506742)
43. Center for Medicare and Medicaid Services: Physician fee schedule search: 2007. http://www.cms.hhs.gov/PFSlookup/02-PFSSearch.asp
44. Red Book 2009: Pharmacy's Fundamental Reference (Red Book Drug Topics). Montvale, NJ, Thompson Healthcare, 2009
45. DesHarnaisCastel L, Bajwa K, Markle JP, et al: A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Support Care Cancer 9:545-551, 2001
46. Black DM, Palermo L, Grima DT: Developing better economic models of osteoporosis: Considerations for the calculation of the relative risk of fracture. Value Health 9:54-58, 2006
47. Howell A, Cuzick J, Baum M, et al: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62, 2005
48. The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, Forbes JF, Cuzick J, et al: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-Month analysis of the ATAC trial. Lancet Oncol 9:45-53, 2008
49. Eastell R, Adams J, Clack G, et al: Long-term effect of anastrozole on bone mineral density: 7-Year results from the ATAC trial. Ann Oncol 22:857-862, 2011
50. Cooke AL, Metge C, Lix L, et al: Tamoxifen use and osteoporotic fracture risk: A population-based analysis. J Clin Oncol 26:5227-5232, 2008
51. Tosteson AN, Rosenthal DI, Melton LJ 3rd, et al: Cost effectiveness of screening perimenopausal white women for osteoporosis: Bone densitometry and hormone replacement therapy. Ann Intern Med 113:594-603, 1990 (Pubitemid 20346189)
52. US Office of Technology Assessment: Effectiveness and Costs of Osteoporosis Screening and Hormone Replacement Therapy. Volume II: Evidence on Benefits, Risks, and Costs. Washington, DC, US Government Printing Office, 1995
53. Lo JC, O'Ryan FS, Gordon NP, et al: Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 68:243-253, 2010
54. Miksad RA, Lai KC, Dodson TB, et al: Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw. Oncologist 16:121-132, 2011
55. US Department of Labor: US consumer price index for medical care for all urban consumers. http://data.bls.gov/cgi-bin/dsrv
56. The Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B, Keshaviah A, et al: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747-2757, 2005
57. Coates AS, Keshaviah A, Thürlimann B, et al: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 25:486-492, 2007 (Pubitemid 350002953)
58. Rabaglio M, Sun Z, Price KN, et al: Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 20:1489-1498, 2009
59. WHO: WHO Fracture Risk Assessment Tool. http://www.shef.ac.uk/FRAX/
60. Ubel PA, Hirth RA, Chernew ME, et al: What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 163:1637-1641, 2003 (Pubitemid 36898950)
61. Gnant M, Mlineritsch B, Schippinger W, et al: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691, 2009
62. Coleman RE, Marshall H, Cameron D, et al: Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 365:1396-1405, 2011
63. Chen Z, Arendell L, Aickin M, et al: Hip bone density predicts breast cancer risk independently of Gail score: Results from the Women's Health Initiative. Cancer 113:907-915, 2008
64. Cauley JA, Lucas FL, Kuller LH, et al: Bone mineral density and risk of breast cancer in older women: The study of osteoporotic fractures - Study of Osteoporotic Fractures Research Group. JAMA 276:1404-1408, 1996 (Pubitemid 26365846)
65. Chlebowski RT, Chen Z, Cauley JA, et al: Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 28:3582-3590, 2010
66. Mauri D, Valachis A, Polyzos NP, et al: Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials. J Natl Compr Canc Netw 8:279-286, 2010
67. National Osteoporosis Foundation: Clinician's guide to prevention and treatment of osteoporosis. http://www.nof.org/professionals/NOF-Clinicians- Guide.pdf
68. Agency for Healthcare Research and Quality: Effective Health Care Program: Comparative effectiveness of treatments to prevent fractures in men and women with low bone density. http://www.effectivehealthcare.ahrq.gov/ehc/ products/8/71/LowBoneDensityFinal.pdf
69. Mincey BA, Duh MS, Thomas SK, et al: Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clin Breast Cancer 7:127-132, 2006 (Pubitemid 44044008)
70. Logman JF, Heeg BM, Botteman MF, et al: Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK. Ann Oncol 21:1529-1536, 2010
71. Jonsson B, Kanis J, Dawson A, et al: Effect and offset of treatment for hip fracture on health outcomes. Osteoporos Int 10:193-199, 1999 (Pubitemid 29458713)
72. Vanachis A, Polyzos NP, Georgonlias V, et al: Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: A meta-analysis. Gynecol Oncol 117:139-145, 2010